Browse by Poster Presenter

Skip to main content

ASCPT 2024 Annual Meeting Main banner

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

A
Abdelgawad, Ibrahim

AbbVie
PII-051 - ELRANATAMAB INTEGRATED EXPOSURE-RESPONSE (ER) EFFICACY AND SAFETY ANALYSES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) USING A CLINICAL UTILITY INDEX (CUI)
Ibrahim Abdelgawad
Favorite
Abdelhady, Ahmed

Intellia Therapeutics
PII-121 - IMPLEMENTATION OF QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING IN TRANSLATION AND DOSE SELECTION FOR FIRST-IN-HUMAN PHASE 1/2 CLINICAL STUDY OF NTLA-2002 IN THE TREATMENT OF HEREDITARY ANGIOEDEMA
Ahmed Abdelhady
Favorite
Aboshady, Omar

College of Pharmacy, Purdue University
OAI-001 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Omar Aboshady
Favorite
PII-007 - CHANGES IN QTC ACROSS DIFFERENT TRIMESTERS OF PREGNANCY AND PRE-ECLAMPSIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Omar Aboshady
Favorite
Adeluola, Adeoluwa

The Ohio State University
PII-048 - APPARENT FCRN DYSFUNCTION IN CANCER CACHEXIA DECREASES EXTRAVASCULAR IMMUNOGLOBULIN G ABSORPTION.
Adeoluwa Adeluola
Favorite
Adeojo, Lilian

Arcus Biosciences Inc.
LB-022 - MULTIPLE ELIMINATION PATHWAYS ARE RESPONSIBLE FOR THE ELIMINATION OF ETRUMADENANT (ETRUMA) AFTER ORAL ADMINISTRATION OF [14C]-ETRUMA TO HUMANS.
Lilian Adeojo
Favorite
Akinola, Lois

U.S. Food and Drug Administration
PT-024 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Lois Akinola
Favorite
PWI-004 - EVIDENCE SUPPORTING EFFICACY EXTRAPOLATIONS FOR TARGETED THERAPIES ACROSS MOLECULARLY DEFINED SUBSETS OF DISEASES IN THE ABSENCE OF SUBSET-SPECIFIC CLINICAL DATA.
Lois Akinola
Favorite
AL Nebaihi, Hamdah

Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta
PII-183 - POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-07265803 AND ITS METABOLITE IN PATIENTS WITH LAMIN A/C RELATED DILATED CARDIOMYOPATHY.
Hamdah AL Nebaihi
Favorite
Alaei, Samaneh

Abbvie Inc
PII-119 - IMPACT OF CRUSHING OR GRINDING ON THE RELATIVE BIOAVAILABILITY OF THE VENETOCLAX TABLETS.
Samaneh Alaei
Favorite
Almond, Lisa

Certara UK (Simcyp)
CT-006 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Lisa Almond
Favorite
CT-007 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Lisa Almond
Favorite
PII-161 - APPLICATION OF PBPK TO ASSESS THE IMPACT OF UGT1A1 GENOTYPE ON DOLUTEGRAVIR EXPOSURE IN PREGNANT WOMEN AND FETUSES
Lisa Almond
Favorite
PII-162 - APPLICATION OF PBPK TO SUPPLEMENT CLINICAL DATA AND INVESTIGATE THE IMPACT OF UGT1A1 PHENOTYPE ON DOLUTEGRAVIR EXPOSURE IN AFRICAN BREASTFED INFANTS
Lisa Almond
Favorite
Alshameri, Naifah

University of Florida
PT-021 - DNA METHYLATION PATTERNS OF ARA-C, DAUNORUBICIN, AND ETOPOSIDE PHARMACOKINETIC/PHARMACODYNAMIC GENES ARE ASSOCIATED WITH THE CLINICAL OUTCOMES IN AML.
Naifah Alshameri
Favorite
Alshammari, Raed

College of Pharmacy, University of Florida
PT-006 - A GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS DIFFERENT METHYLATION PATTERNS AND MECHANISTIC CLUES OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW.
Raed Alshammari
Favorite
AlvarezBaron, Claudia

U.S. Food and Drug Administration
PII-217 - MULTI-CARDIAC ION CHANNEL BLOCK PROFILES FOR LOPINAVIR, RITONAVIR, CHLOROQUINE AND VANOXERINE ALIGN WITH CLINICAL ECG CHANGES AND PROARRHYTHMIA: TWO CASE STUDIES IN SUPPORT OF THE CIPA INITIATIVE.
Claudia AlvarezBaron
Favorite